EX-2.3 4 v367324_ex2-3.htm EXHIBIT 2.3

 

Exhibit 2.3

 

ASSIGNMENT AND ASSUMPTION AGREEMENT

 

THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Assumption Agreement”), dated as of February 2, 2014 is by and among Galmed International Limited, a company incorporated under the laws of Malta (the “Assignor”) and Galmed Research and Development Ltd., a company incorporated under the laws of the state of Israel (the “Assignee”).

 

WHEREAS, the Assignor is part of a world-wide group of companies which engage in the research, development and commercialization of a novel therapy for the treatment of a certain liver disease, and is also known as the Galmed Group (the “Group”); and

 

WHEREAS, the Assignor wishes to transfer and assign to the Assignee all of its intellectual property as part of a broader restructuring of the operations of the Group; (the “Restructure”); and

 

WHEREAS, pursuant to the tax ruling received by the Group from the Israeli Tax Authority (the “ITA Ruling”), the abovementioned and Restructure shall be exempt from tax in Israel, subject to the terms and conditions of the ITA Ruling; and

 

WHEREAS, the Assignee was incorporated on October 27, 2013 for purposes of receiving and assuming the Assigned Assets (as defined below) Assignor; and

 

NOW, THEREFORE, in consideration of the foregoing premises and for no other consideration, whether directly or indirectly, the receipt and sufficiency of which is hereby acknowledged:

 

1.         Assignment and Assumption of Assets. The Assignor hereby assigns transfers and conveys to the Assignee and the Assignee assumes and agrees to honor, perform and discharge promptly when due, the Assumed Assets, as specified in Schedule A hereto.

 

2.         Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Israel without reference to any principles of conflicts of law.

 

3.         Third-Party Beneficiaries; Successors; Assigns. Nothing in this Assumption Agreement, express or implied, is intended or shall be construed to create any third-party beneficiaries. This Assumption Agreement shall be binding upon and inure solely for the benefit of the parties and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person any rights, interests, benefits or remedies of any nature whatsoever under or by reason of this Assumption Agreement.

 

4.         Counterparts; Headings. This Assumption Agreement may be executed in multiple counterparts, each of which when so executed shall be an original, but all of which together shall constitute one agreement. Facsimile and Email signatures shall be deemed original signatures. The headings of articles and sections hereof were inserted solely for convenience of reference and shall not affect the interpretation hereof.

 

 
 

 

IN WITNESS WHEREOF, the parties have caused this Assumption Agreement to be duly executed as of the date first above written.

 

  Galmed International Limited Galmed Research and Development Ltd.
     
By: /s/ Allen Baharaff   By: /s/ Allen Baharaff
Name:  Allen Baharaff   Name:  Galmed Pharmaceuticals Ltd. (by Allen Baharaff)
Title: Director   Title: Director

 

 
 

 

SCHEDULE A

 

Assigned Assets

 

 

CONFIDENTIAL

 

Patent Family Report

 

File No. :          GILAT/002 Priority : US Prov. 02/Feb/2009

 

Title :                   METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE

 

Abstract :The present invention relates to methods for treatment, prevention, and inhibition of progression of Alzheimer's disease, Cerebral Amyloid Angiopathy (CAA), and other brain diseases characterized by amyloid plaque deposits, comprising the administration to a subject of a bile acid or bile salt fatty acid conjugate (FABAC).

 

Country   Application
No.		   Filing Date   Patent No.\
Pub. No.		   Issue Date\
Pub. Date		   Status
                     
Europe   10706394.3   01/Feb/2010   2391370   07/Dec/2011   examination
Israel   214340   01/Feb/2010   214340   31/Jan/2013   examination
PCT   PCT/IL2010/000088   01/Feb/2010   WO2010/086864   05/Aug/2010   expired
US Prov.   61/024911   31/Jan/2008           expired
US Prov.-l   61/149100   02/Feb/2009           expired
USA   13/147071   01/Feb/2010   US2012/0157419   21/Jun/2012   filed

 

19/12/2013

 

 
 

 

CONFIDENTIAL

 

Patent Family Report

 

File No. :         GILAT/003 Priority : Israel 08/Apr/1998

 

Title :FATTY ACID DERIVATIVES OF BILE ACIDS AND BILE ACID DERIVATIVES

 

Abstract :The present invention relates to bile acid or bile salt fatty acid conjugates (hereinafter called 'BAFAC'), to their use in dissolving cholesterol gallstones in bile, preventing their occurrence or recurrence, to their use in reducing or preventing arteriosclerosis and to methods for the treatment of said diseases. The conjugates are of the formula W - X - G in which G is a bile acid or bile salt radical, W stands for one or two saturated fatty acid radicals and X is either a direct bond or a bonding member between said bile acid or bile salt and the fatty acid(s). The conjugation is advantageously performed at a position selected among the 3, 6, 7, 12 and 24 positions of the bile acid or bile salt nucleus. The fatty acids are preferably saturated fatty acids having (14 - 22) carbon atoms.

 

Country   Application
No.		   Filing Date   Patent No.\
Pub. No.		   Issue Date\
Pub. Date		   Status
                     
Australia   30515/99   25/Mar/1999   742944   02/May/2002   granted
Austria       25/Mar/1999   1071702       granted
Belgium       25/Mar/1999   1071702       granted
Brazil   PI9909908-0   25/Mar/1999           examination
Canada   2325933   25/Mar/1999   2325933   10/Jun/2008   granted
China   99804903.4   25/Mar/1999   ZL99804903.4   07/May/2008   granted
Cyprus       25/Mar/1999   1071702       granted
Czech Republic   PV2000-3625   25/Mar/1999   300824   08/Jul/2009   granted
Denmark       25/Mar/1999   1071702       granted
EURASIA   200000888   25/Mar/1999   003392   24/Apr/2003   granted
Europe   99912026.4   25/Mar/1999   1071702   28/Aug/2002   granted
Finland       25/Mar/1999   1071702       granted
France       25/Mar/1999   1071702       granted
Germany       25/Mar/1999   1071702       granted
Greece       25/Mar/1999   1071702       granted
Hungary   P0101653   25/Mar/1999           allowance
Indonesia   W-20001998   25/Mar/1999   ID0014395   08/0ct/2004   granted
Ireland       25/Mar/1999   1071702       granted
Israel   123998   08/Apr/1998   123998   30/Dec/2004   granted
Italy       25/Mar/1999   1071702       granted
Japan   2000-543488   25/Mar/1999   5031942   06/Jul/2012   granted
Korea   10-2000-7010903   25/Mar/1999   615560   17/Aug/2006   granted
Latvia       25/Mar/1999   1071702       granted
Lithuania       25/Mar/1999   1071702       granted
Luxembourg       25/Mar/1999   1071702       granted
Mexico   PA/a/2000/009863   25/Mar/1999   225070   16/Dec/2004   granted
Monaco       25/Mar/1999   1071702       granted
Netherlands       25/Mar/1999   1071702       granted
New Zealand   507309   25/Mar/1999   507309   06/0ct/2003   granted
Norway   20004998   25/Mar/1999   316875   07/Jun/2004   granted
Poland   P-343360   25/Mar/1999   199271   08/Feb/2008   granted
Portugal       25/Mar/1999   1071702       granted
Romania       25/Mar/1999   1071702       granted
Slovenia       25/Mar/1999   1071702       granted
Spain       25/Mar/1999   1071702       granted
Sweden       25/Mar/1999   1071702       granted
Switzerland       25/Mar/1999   1071702       granted
Turkey   84564   25/Mar/1999   TR 2000 02876   09/Dec/2003   granted
UK       25/Mar/1999   1071702       granted
Ukraine   20000095546   25/Mar/1999   70318   15/0ct/2004   granted
USA   09/693928   25/Mar/1999   6384024   07/May/2002   granted
USA-1   09/675656   25/Mar/1999   6395722   28/May/2002   granted
USA-2   10/078671   25/Mar/1999   6589946   08/Jul/2003   granted

 

19/12/2013

 

 
 

 

CONFIDENTIAL

 

Patent Family Report

 

File No. :          GILAT/004 Priority : Israel 17/Apr/2001

 

Title :USE OF BILE ACID OR BILE SALT FATTY ACID CONJUGATES

 

Abstract :The present invention relates to the use of a bile acid or bile salt fatty acid conjugate of general formula II W - X - G in which G is a bile acid or bile salt radical, which, if desired, is conjugated in position 24 with a suitable amino acid, W stands for one or two fatty acid radicals having 14-22 carbon atoms and X stands for a suitable bonding member or for a direct C=C bond between said bile acid or bile salt radical and the fatty acid(s) or of a pharmaceutical composition comprising same for the reduction of Cholesterol in blood, for the treatment of Fatty Liver, Hyperglycemia and Diabetes.

 

Country   Application
No.		   Filing Date   Patent No.\
Pub. No.		   Issue Date\
Pub. Date		   Status
                     
Australia   2002307771   15/Apr/2002   2002307771   16/Feb/2007   granted
Australia-1 Div   2007200191   15/Apr/2002   2007200191   18/Dec/2008   granted
Austria   02761957.6   15/Apr/2002   E365044   20/Jun/2007   granted
Belgium   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Belgium-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Canada   2444266   15/Apr/2002   2444266   27/Jul/2010   granted
Canada-1 Div   2703688   15/Apr/2002   2703688   31/Jul/2012   granted
China   02808187.0   15/Apr/2002   ZL02808187.0   21/Jun/2006   granted
Cyprus   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Czech Republic   PV 2003-2710   15/Apr/2002   300489   22/Apr/2009   granted
Czech Republic-1 Div   PV 2008-296   15/Apr/2002           filed
Denmark   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Denmark-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
EURASIA   200301017   15/Apr/2002   007565   29/Dec/2006   granted
Europe   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Europe-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   granted
Finland   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Finland-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
France   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
France-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Germany   02761957.6   15/Apr/2002   60220775-4   20/Jun/2007   granted
Germany-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Greece   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Greece-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Hungary   P04 00801   15/Apr/2002           filed
Indonesia   W-00 2003 02033   15/Apr/2002   ID0020054   06/Nov/2007   granted
Indonesia-1 Div   W-00 2007 000430   15/Apr/2002   ID P 0023712   30/Jun/2009   granted
Ireland   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Ireland-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Israel   142650   17/Apr/2001   142650   04/Sep/2007   granted
Italy   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Italy-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Japan   2002-580951   15/Apr/2002   4324706   19/Jun/2009   granted

 

19/12/2013

 

 
 

 

CONFIDENTIAL

 

Patent Family Report

 

Korea   10-2003-7013339   15/Apr/2002   0883080   04/Feb/2009   granted
Luxembourg   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Mexico   PA/a/2003/009553   15/Apr/2002   246214   06/Jun/2007   granted
Mexico-1 Div   MX/a/2007/003451   15/Apr/2002   277418   20/Jul/2010   granted
Monaco   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Netherlands   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Netherlands-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
New Zealand   528868   15/Apr/2002   528868   12/Jan/2006   granted
Norway   20034609   15/Apr/2002   333910   14/0ct/2013   granted
Norway-1   20131219   15/Apr/2002           filed
Poland   P-366585   15/Apr/2002   205057   07/Sep/2010   granted
Poland-1 div   P-387458   27/Feb/2009   211438   03/Nov/2011   granted
Portugal   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Portugal-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Spain   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Spain-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Sweden   02761957.6   15/Apr/2002   02761957-6   20/Jun/2007   granted
Sweden-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Switzerland   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Switzerland-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Turkey   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
Turkey-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
UK   02761957.6   15/Apr/2002   1379254   20/Jun/2007   granted
UK-1 Div   07002485.6   15/Apr/2002   1790346   03/Jun/2009   validation
Ukraine   2003-109404   15/Apr/2002   78699   23/Apr/2007   granted
USA   10/474032   15/Apr/2002   7501403   10/Mar/2009   granted
USA-1   12/361291   28/Jan/2009   8110564   07/Feb/2012   granted
USA-2   13/366796   06/Feb/2012   US2012/0214872   23/Aug/2012   filed

 

19/12/2013

 

 
 

 

CONFIDENTIAL

 

Patent Family Report

 

File No. : GILAT/007

 

Country   Application
No.		   Filing Date   Patent No.\
Pub. No.		   Issue Date\ 
Pub. Date		   Status
                     
US Prov.   61/911477   04/Dec/2013           filed

 

19/12/2013

 

 
 

 

CONFIDENTIAL

 

Patent Family Report

 

File No. : GILAT/008

 

Country   Application
No.		   Filing Date   Patent No.\
Pub. No.		   Issue Date\ 
Pub. Date		   Status
                     
US Prov.   61/911478   04/Dec/2013           filed

 

19/12/2013